Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Eur J Cancer Prev. 2020 Sep;29(5):452-457. doi: 10.1097/CEJ.0000000000000565.
To investigate trends in prevalence of various human papillomavirus types in order to assess the unmet clinical needs for women affected by human papillomavirus-related disease. Data of consecutive 15 138 patients undergoing human papillomavirus DNA testing from 1998 to 2018 were retrospectively identified. Human papillomavirus types were classified at high-risk according to the classification of the International Agency for Research on Cancer. The International Agency for Research on Cancer included seven human papillomavirus types covered by nine-valent vaccine and five not yet covered by any available vaccines. Overall, 4159 (65.3%), 1500 (23.5%) and 714 (11.2%) women had human papillomavirus types covered by nine-valent vaccination, not covered by nine-valent vaccination and co-infections of human papillomavirus types of both groups. At least one high-risk human papillomavirus type(s) was detected in 1241 patients with genital dysplasia: 832 (67.1%), 291 (23.4%) and 118 (9.5%) women had human papillomavirus types covered by nine-valent vaccination, not covered by nine-valent vaccination and co-infections of human papillomavirus types of both groups. Over the twenty-year study period, the number of human papillomavirus types not covered by nine-valent vaccine increased dramatically (from 4 to 16%; P < 0.001, P for trend). Similarly, looking at patients with genital dysplasia, high-risk human papillomavirus types not covered by nine-valent vaccine increased from 3 to 13% (P < 0.001, P for trend). Our data highlight that human papillomavirus types covered by nine-valent vaccine represent are the main types associated with genital dysplasia. However, over the study period, we observed an increasing prevalence of confections and high-risk human papillomavirus types not covered by the nine-valent vaccine, thus suggesting the need of developing more complete vaccines against human papillomavirus.
为了调查各种人乳头瘤病毒（HPV）类型的流行趋势，从而评估受 HPV 相关疾病影响的女性的未满足的临床需求。回顾性分析了 1998 年至 2018 年期间连续 15138 名接受 HPV DNA 检测的患者的数据。根据国际癌症研究机构（IARC）的分类，将 HPV 类型分为高危型。IARC 包括九价疫苗涵盖的七种 HPV 类型和五种尚未被任何现有疫苗涵盖的 HPV 类型。总体而言，4159 名（65.3%）、1500 名（23.5%）和 714 名（11.2%）女性的 HPV 类型分别被九价疫苗、九价疫苗未涵盖的类型和两种疫苗都涵盖的 HPV 类型所覆盖。在至少有一种生殖器发育不良的高危 HPV 类型的 1241 名患者中：832 名（67.1%）、291 名（23.4%）和 118 名（9.5%）女性的 HPV 类型分别被九价疫苗、九价疫苗未涵盖的类型和两种疫苗都涵盖的 HPV 类型所覆盖。在二十年的研究期间，九价疫苗未涵盖的 HPV 类型数量显著增加（从 4%增加到 16%；P<0.001，趋势 P 值）。同样，在生殖器发育不良的患者中，九价疫苗未涵盖的高危 HPV 类型从 3%增加到 13%（P<0.001，趋势 P 值）。我们的数据强调了九价疫苗涵盖的 HPV 类型是与生殖器发育不良相关的主要类型。然而，在研究期间，我们观察到九价疫苗未涵盖的 HPV 类型和高危 HPV 类型的流行率增加，因此表明需要开发针对 HPV 的更完整的疫苗。
